Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1498)

GRANT OF AWARD SHARES PURSUANT TO THE SHARE AWARD SCHEME

Reference is made to the announcement of PuraPharm Corporation Limited (the "Company") dated 22 February 2016 (the "Announcement") in relation to the adoption of the Scheme. Unless otherwise defined in this announcement, capitalised terms used in this announcement shall have the same meanings ascribed to them in the Announcement.

On 16 June 2017 (the "**Date of Grant**"), the board (the "**Board**") of directors (the "**Directors**") of the Company resolved to grant a total of 2,050,000 Shares (the "**Awarded Shares**") to 18 persons (together the "**Awardees**") who are Eligible Participants pursuant to the Scheme as at the date of this announcement. Details of the grant are as follows:

Name of Awardees	Position	Number of Awarded Shares Granted
Mr. Chan Yu Ling, Abraham Dr. Tsoi Kam Biu, Alvin Mr. Chan Lung Sang Ms. Man Yee Wai, Viola Mr. Chan Kin Man, Eddie Dr. Chan Kin Keung, Eugene Mr. Ho Kwok Wah, George Dr. Leung Lim Kin, Simon Prof. Tsui Lap Chee Remaining nine Awardees who are Eligible Employees and are not connected persons (as defined in	Executive director Executive director Executive director Executive director Non-executive director Independent non-executive director Independent non-executive director Independent non-executive director Independent non-executive director	300,000 150,000 150,000 20,000 20,000 20,000 20,000 20,000 20,000
the Listing Rules) of the Company		1,200,000
Total		2,050,000

The Awarded Shares shall be vested in five tranches in accordance with the following dates: (i) 30% shall be vested on the first anniversary of the Date of Grant, i.e. 16 June 2018; (i) 20% shall be vested on the second anniversary of the Date of Grant, i.e. 16 June 2019; (iii) 20% shall be vested on the third anniversary of the Date of Grant, i.e. 16 June 2020; (iv) 20% shall be vested on the fourth anniversary of the Date of Grant, i.e. 16 June 2021; and (v) 10% shall be vested on the fifth anniversary of the Date of Grant, i.e. 16 June 2022.

The award of the Awarded Shares to Directors forms part of their respective remuneration packages and is exempt from the reporting, announcement and independent shareholders' approval requirements under the Listing Rules. Based on the closing price of HK\$3.73 per Share on the date of the grant of the Awarded Shares, the market value of the 2,050,000 Awarded Shares in aggregate is HK\$7,646,500. Pursuant to the Scheme Rules, the Awarded Shares have been granted to the grantees of such Awarded Shares for nil consideration. The Awarded Shares have been purchased and are held by the Trustee in accordance with the Scheme Rules and subject to the terms of the Trust Deed. The Awarded Shares granted shall vest in the Selected Participants in accordance with the Scheme Rules.

The grant of the Awarded Shares to each of the above Directors has been approved by the independent non-executive Directors (excluding the independent non-executive Director who is the Awardee of the Awarded Shares).

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 16 June 2017

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Lung Sang and Ms. Man Yee Wai, Viola; the non-executive director of the Company is Mr. Chan Kin Man, Eddie; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.